Suneeta Meena1, Sarita Mohapatra2, Seema Sood3, Benu Dhawan3, Bimal Ku Das3, Arti Kapil3. 1. Senior Resident, Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India. 2. Assistant Professor, Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India. 3. Professor, Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
Abstract
INTRODUCTION: Enterococcal infection has emerged as a major therapeutic challenge. Emergence of High Level Aminoglycoside Resistance (HLAR) and Vancomycin-Resistant Enterococcus (VRE) has further limited the drug therapy in enterococcal infections. However, nitrofuratoin being an old drug reported to have less resistance in comparison to the other classes of antimicrobial agents. AIM: To detect susceptibility of nitrofurantoin against VRE isolates from Urinary Tract Infection (UTI) of outdoor and indoor patient departments. MATERIALS AND METHODS: An observational study was carried out at a tertiary care hospital in New Delhi over a period of six months (from November 2015 to April 2016). A total of 14,714 urine samples were collected and processed from the patients symptomatic for UTI. The enterococcal isolates were identified and confirmed by standard phenotypic tests. The antimicrobial susceptibility tests of isolated organisms were performed by Kirby-Bauer Disc Diffusion Method as per Clinical and Laboratory Standards Institute (CLSI) 2015 guidelines. The Wilcoxon rank-sum (Mann-Whitney) test was used to compare continuous variables. Chi-square or Fisher's exact tests were used to compare categorical variables. p<0.05 was considered as significant. RESULTS: A total of 70 enterococci species {Enterococcus faecalis (n=9), Enterococcus faecium, (n=61)} were isolated. Twenty six out of 70 isolates were observed resistant to vancomycin. Among 26 VRE, 21(80.76%) were susceptible to nitrofurantoin. Both the species {E. faecalis (80.32%) and E. faecium (88.8%)} were uniformly susceptible to nitrofurantoin. CONCLUSION: Nitrofurantoin has retained antimicrobial efficacy against emerging VRE in vitro and can be used for treatment of enterococcal urinary tract infections.
INTRODUCTION:Enterococcal infection has emerged as a major therapeutic challenge. Emergence of High Level Aminoglycoside Resistance (HLAR) and Vancomycin-Resistant Enterococcus (VRE) has further limited the drug therapy in enterococcal infections. However, nitrofuratoin being an old drug reported to have less resistance in comparison to the other classes of antimicrobial agents. AIM: To detect susceptibility of nitrofurantoin against VRE isolates from Urinary Tract Infection (UTI) of outdoor and indoor patient departments. MATERIALS AND METHODS: An observational study was carried out at a tertiary care hospital in New Delhi over a period of six months (from November 2015 to April 2016). A total of 14,714 urine samples were collected and processed from the patients symptomatic for UTI. The enterococcal isolates were identified and confirmed by standard phenotypic tests. The antimicrobial susceptibility tests of isolated organisms were performed by Kirby-Bauer Disc Diffusion Method as per Clinical and Laboratory Standards Institute (CLSI) 2015 guidelines. The Wilcoxon rank-sum (Mann-Whitney) test was used to compare continuous variables. Chi-square or Fisher's exact tests were used to compare categorical variables. p<0.05 was considered as significant. RESULTS: A total of 70 enterococci species {Enterococcus faecalis (n=9), Enterococcus faecium, (n=61)} were isolated. Twenty six out of 70 isolates were observed resistant to vancomycin. Among 26 VRE, 21(80.76%) were susceptible to nitrofurantoin. Both the species {E. faecalis (80.32%) and E. faecium (88.8%)} were uniformly susceptible to nitrofurantoin. CONCLUSION:Nitrofurantoin has retained antimicrobial efficacy against emerging VRE in vitro and can be used for treatment of enterococcal urinary tract infections.
Authors: Céline Pulcini; Karen Bush; William A Craig; Niels Frimodt-Møller; M Lindsay Grayson; Johan W Mouton; John Turnidge; Stephan Harbarth; Inge C Gyssens Journal: Clin Infect Dis Date: 2012-01-15 Impact factor: 9.079
Authors: G Werner; T M Coque; A M Hammerum; R Hope; W Hryniewicz; A Johnson; I Klare; K G Kristinsson; R Leclercq; C H Lester; M Lillie; C Novais; B Olsson-Liljequist; L V Peixe; E Sadowy; G S Simonsen; J Top; J Vuopio-Varkila; R J Willems; W Witte; N Woodford Journal: Euro Surveill Date: 2008-11-20
Authors: Alessio Sposato; Marco Cordisco; Giuseppe de Ruvo; Silvia Ferro; Rossana Alessandra Raineri; Adriana Trotta; Domenico Buonavoglia; Marialaura Corrente Journal: Vet Med Sci Date: 2022-05-13
Authors: Haley Sanderson; Rodrigo Ortega-Polo; Kevin McDermott; Geoffrey Hall; Rahat Zaheer; R Stephen Brown; Anna Majury; Tim A McAllister; Steven N Liss Journal: Microorganisms Date: 2019-11-29